AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
Monday, 03 August 2015
AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments.
Findings provide more data that fish oil supplements' clear benefit is suspect
Friday, 31 July 2015
The importance of a diet rich in fish oils - now a billion dollar food-supplement industry - has been debated for over half a century. A few large clinical trials have supported the idea that fish oils confer therapeutic benefits to patients with cardiovascular disease. Researchers think that hearts and blood vessels may benefit in part from their anti-inflammatory properties.
Merck, a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials, is calling for national and international start-ups to apply for funding of innovative ideas by August 14, 2015.
The Bayer Group continued to grow sales in the second quarter of 2015 and significantly increased earnings. Sales of HealthCare increased by 28.0 percent (Fx & portfolio adj. 8.3 percent) to EUR 5,908 million in the second quarter (Q2 2014: EUR 4,615 million).
Pharmaceutical firms "underinvest" in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study co-authored by MIT economists. Specifically, drugs to treat late-stage cancers are less costly to develop than drugs for earlier-stage cancers, partly because the late-stage drugs extend people's lives for shorter durations of time.
AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa
Monday, 27 July 2015
AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine. Caprelsa was granted Orphan Drug Designation by the US FDA in 2005 and is currently available in 28 countries for the treatment of aggressive and symptomatic medullary thyroid carcinoma, with global product sales of $48 million in 2014.
Toxin from salmonid fish has potential to treat cancer
Friday, 24 July 2015
Pathogenic bacteria develop killer machines that work very specifically and highly efficiently. Scientists from the University of Freiburg have solved the molecular mechanism of a fish toxin that could be used in the future as a medication to treat cancer. The scientists have now published their research in the journal Nature Communications.